SynthesisSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.
Synthesis in Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments forWorld journal of gastroenterology · 2019Trial
- Antiparasitic Activity ofVeterinary sciences · 2026Article
- [Study on the Inhibitory Effect and Mechanism of Trans-2-Decenal onSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- Diagnosis and treatment ofFuture microbiology · 2025Review
- Overcoming antibiotic-resistantWorld journal of gastroenterology · 2025Review
- PCR-based RFLP and ERIC-PCR patterns of Helicobacter pylori strains linked to multidrug resistance in Egypt.Scientific reports · 2024Observational
- Newer, Older, and Alternative Agents for the Eradication ofAntibiotics (Basel, Switzerland) · 2023Review
- The State of the Art of Molecular Fecal Investigations forInternational journal of molecular sciences · 2023Review
- Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.Nature reviews. Gastroenterology & hepatology · 2021Review
- Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021Article
- Antibiotic resistance pattern and frequency of cagA and vacA genes in Helicobacter pylori strains isolated from patients in Tabriz city, Iran.BMC research notes · 2021Article
- Comparing the Effect of Two Low-dose and High-dose Four-drug Regimens of Furazolidone in EradicatingMiddle East journal of digestive diseases · 2021Article
- Outcomes of furazolidone- and amoxicillin-based quadruple therapy forWorld journal of gastroenterology · 2018Article
- Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran.Digestive diseases and sciences · 2017Review
- Curcumin Ameliorates Furazolidone-Induced DNA Damage and Apoptosis in Human Hepatocyte L02 Cells by Inhibiting ROS Production and Mitochondrial Pathway.Molecules (Basel, Switzerland) · 2016Article
- Furazolidone and Helicobacter pylori Treatment.Middle East journal of digestive diseases · 2015Article
- Attempts to enhance the eradication rate of Helicobacter pylori infection.World journal of gastroenterology · 2014Review
- Helicobacter pylori: future perspectives in therapy reflecting three decades of experience.World journal of gastroenterology · 2014Review
- How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?World journal of gastroenterology · 2013Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimFurazolidone-based therapies are used in developing countries to cure Helicobacter pylori infection due to its low cost. The low bacterial resistance toward furazolidone may render appealing the use of this drug even in developed countries. However, some relevant safety concerns do exist in using furazolidone. PATIENTS AND
methodsThis was a systematic review with pooled-data analysis of data regarding both eradication rate and safety of furazolidone-based therapies for H. pylori infection. Intention-to-treat (ITT) and per-protocol (PP) eradication rates were calculated.
resultsFollowing furazolidone-based first-line therapy, H. pylori eradication rates were 75.7% and 79.6% at ITT and PP analysis, respectively (P<0.001). The overall incidence of side effects and severe side effects were 33.2% and 3.8%, respectively. At multivariate analysis, only high-dose furazolidone was associated with increased therapeutic success (OR: 1.5, 95% CI: 1.3-2.7; P<0.001), while occurrence of side effects was relevant following treatment for a long duration (OR: 2.9, 95% CI: 2.2-4.1; P<0.001), high-dose furazolidone (OR: 2.3, 95% CI: 1.7-3.2; P<0.001) and bismuth-containing regimens (OR: 2.1, 95% CI: 1.5-2.8; P<0.001).
conclusionsFurazolidone-based regimens usually achieve low eradication rates. Only a high-dose regimen improves the cure rate, but simultaneously increases the incidence of severe side effects. Therefore, we suggest that patients have to be clearly informed about the possible genotoxic and carcinogenetic effects for which furazolidone use is not approved in developed countries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.